BioTime, Inc: Cell therapy co developing OpRegen in Ph 1/2 development for dry-AMD, OPC1 in Ph 1/2 development for spinal cord injury and VAC2 in Ph 1 development for NSCLC. Also developing Renevia as a cell delivery platform for HIV lipoatrophy (CE Mark response expected 2H19). Recently acquired Asterias Biotherapeutics (AST), spun off AgeX (AGEX) and currently hold 28% of OncoCyte (OCX).
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
USA
Disease Space
Ophthalmology
Listing
Public, USA
Market Cap
100MM - 500MM
Website:
Address:
1010 Atlantic Avenue, Suite 102
Alameda, CA 94501-1147
United States

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Upcoming Company Event Participation

Hamptons CEO Roundtable 2019

Bridgehampton, August 15, 2019

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2017 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.